levofloxacin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   137 Trials   137 Trials   5343 News 


«12...3536373839404142434445...9091»
  • ||||||||||  Cayston (aztreonam lysine) / Gilead
    Review, Journal:  Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. (Pubmed Central) -  Nov 15, 2022   
    More evidence from trials measuring similar outcomes in the same way is needed to determine a better measure of benefit. Longer-term trials are needed to look at the effect of inhaled antibiotics on quality of life, survival and nutritional outcomes.
  • ||||||||||  Tubo-ovarian Abscess in a Non-sexually Active Adolescent Female: an Uncommon Diagnosis (Anaheim Convention Center, Hall A, Board # 186) -  Nov 10, 2022 - Abstract #AAPNCE2022AAP_NCE_2156;    
    This case highlights that early recognition is key to diagnosis and appropriate management of TOA in a non-sexually active adolescent female. A multi-disciplinary approach is critical to optimize therapeutic options including antibiotics, surgery, and IR drainage.
  • ||||||||||  AzaSite (1% azithromycin ophthalmic solution) / Sun Pharma, Akorn, Nicox
    Trial completion, Trial completion date, Trial primary completion date:  Healthy Patients & Effect of Antibiotics (clinicaltrials.gov) -  Nov 10, 2022   
    P=N/A,  N=20, Completed, 
    Their modes of action, resistance mechanism, detection and analysis methods, and remediation strategies have also been discussed in detail. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Aug 2022 | Trial primary completion date: Dec 2022 --> Aug 2022
  • ||||||||||  levofloxacin / Generic mfg., rifampicin / Generic mfg., minocycline / Generic mfg.
    Journal:  Leprosy chemoprophylaxis of household contacts: A survey of Canadian infectious disease and tropical medicine specialists. (Pubmed Central) -  Nov 8, 2022   
    Such convenient extraction methods and the use of stable isotope-labelled drugs as internal standards provide an accurate and precise quantification of plasma concentrations of all major clinically-used antiTB drugs regimens and is optimally suited for clinically efficient TDM against tuberculosis. Consensus among Canadian infectious diseases specialists is lacking regarding leprosy PEP and screening of household contacts.
  • ||||||||||  Journal:  The Clinical Features and Management of Empyema Caused by Streptococcus constellatus. (Pubmed Central) -  Nov 5, 2022   
    constellatus were sensitive to penicillin G, linezolid, levofloxacin, vancomycin, ceftriaxone, and chloramphenicol, resistant to erythromycin, tetracycline, and clindamycin...constellatus often co-isolated with anaerobes in empyema. Antibiotics should cover simultaneously both S. constellatus and anaerobes.
  • ||||||||||  IV Antibiotic Use during Autologous Hematopoietic Stem Cell Transplantation Is Associated with Inferior Survival in Patients with Multiple Myeloma (ENMCC - Hall D) -  Nov 4, 2022 - Abstract #ASH2022ASH_4823;    
    Two hundred thirty-seven subjects received IV antibiotics including cefepime or piperacillin/tazobactam and vancomycin predominantly to treat neutropenic fever...This finding supports a growing body of literature describing adverse long-term clinical impact of antibiotic exposure and on outcomes in cellular therapy, which we hypothesize is related to deleterious effects of antibiotic exposure on the gut microbiome. Larger prospective studies are necessary to further examine this relationship on myeloma outcomes.
  • ||||||||||  levofloxacin / Generic mfg.
    Journal:  Fractionation of levofloxacin and ofloxacin during their transport in NOM-goethite: Batch and column studies. (Pubmed Central) -  Nov 4, 2022   
    The EF values in the effluent increased with retention time and reached the largest values (0.59-0.72) at around 1.5 pore volume (PV), and then decreased again, reaching a stable value at 5.0-30.0 PV. Both batch and column experiments showed that, fractionation of LEV and OFL occurred during adsorption and transport in the presence of NOM-goethite complexes, which would eventually affect their environmental fate.
  • ||||||||||  Clinical, Review, Journal:  Antimicrobial resistance in patients with odontogenic infections: A systematic scoping review of prospective and experimental studies. (Pubmed Central) -  Nov 3, 2022   
    Streptococcus had resistance to metronidazole, clindamycin, doxycycline, penicillin, and amoxicillin...Gram-negative microorganisms had resistance to tetracycline, ciprofloxacin, azithromycin, amoxicillin, erythromycin, and penicillin...exhibited resistance to penicillin, erythromycin, and gentamicin...showed resistance to penicillin, amoxicillin, erythromycin, clindamycin, levofloxacin, and imipenem...displayed resistance to ampicillin, amoxicillin, moxifloxacin, and cefalexin...A preponderance of anaerobic microorganisms over aerobic ones was observed. Key words:Antibiotic resistance, odontogenic infections, efficacy, microorganisms, scoping review.
  • ||||||||||  levofloxacin / Generic mfg.
    Journal:  Synergies in antimicrobial treatment by a levofloxacin-loaded halloysite and gold nanoparticles with a conjugation to a cell-penetrating peptide. (Pubmed Central) -  Nov 3, 2022   
    Concisely, the structure of the designed nano-cargo has been investigated by various methods, and the in vitro cellular experiments (zone of inhibition and colony-counting) have disclosed that the antimicrobial activity of the lvx is significantly enhanced through incorporation into the HNT/Au-CPP delivery system (drug content: 16 wt%), in comparison with the individual lvx with the same dosage. Hence, it can be stated that the bacterial resistance against antibiotics and the toxic effects of the chemical medications are reduced through the application of the presented strategy.
  • ||||||||||  Journal:  Helicobacter pylori Antibiotic Resistance in Egypt: A Single-Center Study. (Pubmed Central) -  Nov 1, 2022   
    In Egyptian patients, H. pylori had >90% resistance to metronidazole and amoxicillin; modest resistance to erythromycin, azithromycin, and clarithromycin; and low resistance to moxifloxacin, and levofloxacin (≤20%). Dual resistance was high for amoxicillin/clarithromycin and amoxicillin/metronidazole, which prefers using quinolones rather than clarithromycin or metronidazole for first-line treatment of H. pylori in Egypt.
  • ||||||||||  Retrospective data, Review, Journal:  Prevalence of ESBL-Producing Enterobacter Species Resistant to Carbapenems in Iran: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Nov 1, 2022   
    However, the resistance rate to carbapenems was relatively low, and these drugs can still be considered as drugs of choice for the treatment of Enterobacter infections in Iran. Nevertheless, continuous monitoring of drug resistance along with antibiotic therapy based on the local data and evaluation of the therapeutic efficacy of new antibiotics or combination therapeutic strategies, such as ceftazidime/avibactam, meropenem/vaborbactam, plazomicin, and eravacycline, is recommended.
  • ||||||||||  Journal:  First report of Klebsiella pneumoniae co-producing OXA-181, CTX-M-55, and MCR-8 isolated from the patient with bacteremia. (Pubmed Central) -  Nov 1, 2022   
    In this case, colistin is often used to treat the infection caused by CRE...Antimicrobial susceptibility testing showed that K. pneumoniae 5589 was resistant to aztreonam, imipenem, meropenem, ceftriaxone, cefotaxime, ceftazidime, levofloxacin, ciprofloxacin, gentamicin, piperacillin-tazobactam, cefepime, and polymyxin B, but sensitive to amikacin...The in vitro conjugation experiments and plasmid sequence probe indicated that the plasmid p5589-OXA-181 and the p5589-mcr-8 were conjugative, which may contribute to the propagation of ARGs. Relevant detection and investigation measures should be taken to control the prevalence of pathogens coharboring bla , bla and mcr-8.
  • ||||||||||  ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg.
    Journal:  A preventable, life-altering case of fluoroquinolone-associated tendonitis. (Pubmed Central) -  Nov 1, 2022   
    These drugs should not be used for uncomplicated infections unless no other antimicrobial treatment is feasible. This article describes a patient who experienced life-altering disability from a fluoroquinolone, reviews the adverse reactions of this drug class, and discusses recommended treatment for acute uncomplicated cystitis and asymptomatic bacteriuria.
  • ||||||||||  levofloxacin / Generic mfg.
    Journal:  Pyrvinium pamoate potentiates levofloxacin against levofloxacin-resistant Staphylococcus aureus. (Pubmed Central) -  Nov 1, 2022   
    PP synergized with levofloxacin both in vitro and in vivo, resulting in ∼1.5 and ∼0.5 log CFU/g reduction against susceptible and resistant S. aureus infections, respectively, as compared with untreated control. Pyrvinium potentiates levofloxacin against levofloxacin-resistant S. aureus.
  • ||||||||||  Nuzyra (omadacycline) / Paratek
    Preclinical, Journal:  Omadacycline Is Highly Active In Vitro against Mycoplasma genitalium. (Pubmed Central) -  Nov 1, 2022   
    We studied 10 isolates and determined that the new semisynthetic aminomethylcycline omadacycline is active against isolates that are resistant to tetracyclines, macrolides, and quinolones. These data suggest that clinical studies should be performed in order to see if omadacycline may be useful to treat urogenital infections caused by M. genitalium.
  • ||||||||||  Cubicin (daptomycin) / Merck (MSD)
    Enrollment status, Trial completion date, Trial initiation date, Trial primary completion date, Surgery:  Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) (clinicaltrials.gov) -  Nov 1, 2022   
    P4,  N=20, Enrolling by invitation, 
    These data suggest that clinical studies should be performed in order to see if omadacycline may be useful to treat urogenital infections caused by M. genitalium. Recruiting --> Enrolling by invitation | Trial completion date: May 2023 --> Oct 2024 | Initiation date: Feb 2021 --> Mar 2022 | Trial primary completion date: May 2023 --> Oct 2024
  • ||||||||||  Journal:  In silico evaluation of WHO-endorsed molecular methods to detect drug resistant tuberculosis. (Pubmed Central) -  Oct 30, 2022   
    PCR-based diagnostic tests were most sensitive for drugs where mechanisms of resistance are well established and localised to small genetic regions or a few prevalent mutations. Approaches using sequencing technologies can provide advantages for drugs where our knowledge of resistance is limited, or where complex resistance signatures exist.
  • ||||||||||  Preclinical, Journal:  In vitro analysis of synergistic combination of polymyxin B with 12 other antibiotics against MDR Acinetobacter baumannii isolated from a Chinese tertiary hospital. (Pubmed Central) -  Oct 30, 2022   
    The results suggest that, for polymyxin B-based combination therapy against MDR A. baumannii as characterized in this hospital, cefperazone-sulbactam may be the best partner, since it has the highest synergistic rate and the best synergistic effect with polymyxin B. Minocycline, imipenem, meropenem, ceftazidime, cefepime, amikacin and sulfamethoxazole also have some synergistic effects with polymyxin B, but piperacillin-tazobactam, ciprofloxacin, levofloxacin and tobramycin show no synergism. None of these 12 antibiotics has an antagonistic effect when combined with polymyxin B.